Janus Henderson Group PLC boosted its holdings in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 198.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,616,427 shares of the biotechnology company's stock after buying an additional 1,739,904 shares during the period. Janus Henderson Group PLC owned approximately 11.27% of Benitec Biopharma worth $33,268,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in BNTC. Franklin Resources Inc. increased its position in shares of Benitec Biopharma by 269.0% during the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after acquiring an additional 2,142,643 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Benitec Biopharma by 134.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after purchasing an additional 1,131,129 shares during the last quarter. Geode Capital Management LLC increased its holdings in Benitec Biopharma by 134.7% during the 4th quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company's stock worth $2,490,000 after purchasing an additional 113,109 shares in the last quarter. MYDA Advisors LLC purchased a new stake in shares of Benitec Biopharma in the fourth quarter worth approximately $632,000. Finally, 683 Capital Management LLC purchased a new stake in shares of Benitec Biopharma in the fourth quarter worth approximately $452,000. 52.19% of the stock is owned by institutional investors.
Benitec Biopharma Stock Down 1.7%
Benitec Biopharma stock traded down $0.24 during mid-day trading on Tuesday, reaching $13.74. 1,825 shares of the company's stock were exchanged, compared to its average volume of 40,888. Benitec Biopharma Inc. has a one year low of $5.74 and a one year high of $16.90. The business's fifty day simple moving average is $13.66 and its 200 day simple moving average is $12.06. The firm has a market capitalization of $351.74 million, a PE ratio of -9.09 and a beta of 0.34.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.12. On average, sell-side analysts forecast that Benitec Biopharma Inc. will post -1.48 earnings per share for the current year.
Insider Buying and Selling
In other news, Director Suvretta Capital Management, L acquired 900,000 shares of Benitec Biopharma stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the transaction, the director now owns 8,793,245 shares of the company's stock, valued at $114,312,185. This trade represents a 11.40% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by insiders.
Analyst Ratings Changes
BNTC has been the topic of several analyst reports. JMP Securities reaffirmed a "market outperform" rating and set a $20.00 target price on shares of Benitec Biopharma in a research report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $28.00 target price on shares of Benitec Biopharma in a research note on Monday. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $24.71.
Read Our Latest Stock Analysis on Benitec Biopharma
About Benitec Biopharma
(
Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
See Also
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
